<DOC>
	<DOCNO>NCT02120950</DOCNO>
	<brief_summary>To collect data reflect efficacy safety aflibercept without photodynamic therapy subject diagnose polypoidal choroidal vasculopathy subtype wet age-related macular degeneration</brief_summary>
	<brief_title>Aflibercept Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Signed informed consent Men woman â‰¥50 year age Diagnosis symptomatic macular Polypoidal Choroidal Vasculopathy ( PCV ) study eye establish Indocyanine Green Angiography ( ICGA ) study center Prior use intravitreal subtenon corticosteroid study eye within 3 month prior study entry Any prior use intraocular anti Vascular Endothelial Growth Factor ( antiVEGF ) agent study eye , systemic use anti VEGF product within 3 month prior study entry Prior macular laser treatment study eye include Photodynamic Therapy ( PDT ) History allergy fluorescein use fluorescein angiography , iodine and/or indocyanine green . History allergy aflibercept , verteporfin , excipients .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PCV</keyword>
</DOC>